Clinical trial · Interventional
Radiomics and Radiogenomics of Non-small Cell Lung Cancer
Radiomics and Radiogenomics of Non-small Cell Lung Cancer: Relationships of Radiomic Signature With Gene Driver Mutations and Implications for Emerging Therapies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the radiomic characteristics and a broad range of genetic aberrations in lung adenocarcinomas will be evaluated. Investigators will assess changes in the radiomic and genetic profiles during targeted therapies in a subset of patients harboring treatable mutations. Patients undergoing targeted therapies will also be evaluated for variations in genomic profile and radiomic signature during follow-up
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiomic signature | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Radiomic signature
- description
- Assessment of radiomic signature and tumor genetic profile at baseline
- interventionNames
- Diagnostic Test: Radiomic signature
Primary outcomes (3)
- measure
- Evaluation of the association between the status of Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), Kirsten Rat Sarcoma Virus (KRAS) and nodal status
- timeFrame
- 1 month
- description
- The status of EGFR, ALK, KRAS will be validated for its association with nodal status at surgery
- measure
- Evaluation of the association between the status of EGFR, ALK, KRAS and overall survival (OS)
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with diagnosis of NSCLC * patients candidates for mutational status assessment Exclusion Criteria: \- patients with age \<18 years
References
Publications (1)
- DERIVEDRanghiero A, Rinaldi L, Netti S, Gaeta A, Attili I, Spitaleri G, Funicelli G, Mora S, Fodor C, Origgi DA, De Marinis F, Fusco N, Rizzo S, Barberis M, Raimondi S, Botta F, Gandini S, Guerini-Rocco E. Radiogenomic approach combining CT-based radiomics and liquid biopsy improves prognostic stratification in patients with advanced NSCLC. J Liq Biopsy. 2026 Apr 26;12:100470. doi: 10.1016/j.jlb.2026.100470. eCollection 2026 Jun. PMID 42095156